Ricky Dillon
Analyst · KeyBanc Capital Markets. Please go ahead
Thanks, Randy, and good morning, everyone. Before we dive into the results for the quarter, I wanted to call out a few of the items included in the adjustments for one-time items on the GAAP to non-GAAP reconciliation in the appendix. First, we've completed the sale of ECS and all of the strategic exit product lines discussed last quarter. Our portfolio actions are complete, and we are positioned to focus on strategy execution going forward. We received $9 million in proceeds from the product line divestitures during the quarter. These proceeds were offset by the net assets associated with the product lines resulting in a net gain of $1 million. Let's move on to the fourth quarter results on Slide 6. Sales of $147 million were higher than our guidance for the quarter. Core sales were flat in the quarter and in line with our expectations. As Randy mentioned, we exceeded our new product vitality goal of 10%, and we believe this achievement along with the improvements we have made in our overall commercial effectiveness is allowing us to outperform the market. Globally, tool sales remain challenged, consistent with global economic indicators and our market outlook for fiscal 2020. Adjusted EBITDA margin improved in the quarter by 100 basis points. The effective tax rate for the quarter was approximately 12% higher than the prior year, but lower than our guidance. The rate for the quarter reflects the timing of new regulations, which had been expected later in the year, so our guidance for the year remains 20%. Despite the higher effective tax rate and the lower sales volume, strong year-over-year margins delivered slightly higher EPS compared to 2019. At $0.12 per share, we were at the top of our guidance range. So turning to our sales waterfall on Slide 7. Core sales were flat for the quarter, both tools and service sales decreased by 1%, respectively. The impact from the strong dollar reduced net sales by an additional 1%, and the impact of strategic exits was approximately $10 million. We saw double-digit growth in Cortland medical products led during the quarter. Tool core sales results were varied by region. North America product sales continued the modest deceleration we saw in Q4. Core tool sales were down low-single digits excluding the impact of a large power-gen order that slipped out of the quarter, but was booked on December 1 at $1 million decline in heavy lift product sales attributable to timing and the lumpy nature of the category. The low single-digit decline is consistent with our expectations for the year and what we are hearing in the market. Our distributors are reporting mixed results with certain regions in North America roughly flat to last year, while others are showing moderate declines especially in certain challenged verticals. None, however, are expecting significant worsening as the quarters continue ahead. Product sales in Europe were up low-double digits versus the prior year. The overperformance was driven by several heavy lift products. Again, removing the impact of the lumpy HLT products, core tool sales were flat year-over-year with demand appearing to stabilize from low-to-mid single-digit declines we saw in the fourth quarter. While certain countries are seeing stronger demand and others are flat to down low-single digits. And the rest of the world was relatively flat. Taking a look at service, our Middle East region continued its strong performance with year-over-year growth in excess of 20% as we continue to capture a series of small unplanned projects in the region. This was offset by the large projects we had in APAC and Europe in the prior year, and as expected, drove the year-over-year decline in service. Lastly, the impact of pricing was negligible for the quarter. If we turn to Slide 8, as I said earlier, despite the reduction in overall sales, our adjusted EBITDA margin improved by 100 basis points, and we were able to hold EBITDA flat despite these volume headwinds. The strategic product and service exits and the benefit from 2019 restructuring actions resulted in improvements in EBITDA that more than offset the impact of volume declines and a mix that favored service and HLT in the current year versus prior year. We also benefited from strong growth in our Medical businesses this quarter. And as we noted, the profit profile for these products are very similar to our tool products. If we turn now to our balance sheet and liquidity on Slide 9, we used approximately $25 million of cash during the quarter versus $36 million in the first quarter of fiscal 2019, which was in line with our expectations. Significantly lower working capital build during the quarter this year and lower bonus payments drove the improvement year-over-year. It's definitely worth noting that both years included cash used by discontinued ECS operations. And in addition to the transaction-related costs, ECS consumed $17 million and $27 million in primary working capital alone in the first quarters of fiscal 2019 and 2020, respectively. Capital expenditures were $5 million down from the $8 million in the prior year. We ended the quarter with $277 million of cash on hand. As Randy noted, following the October 31 close of ECS transaction, we paid off our term loan, leaving $286 million of long-term bonds as the remaining debt outstanding. We also bought back approximately 840,000 shares of stock at a cost of approximately $18 million during the quarter, both consistent with our capital allocation priorities as we manage our balance sheet and opportunistically return capital to our shareholders. Our leverage now sits at 0.8x versus 2.1x in Q1 of 2019. Our balance sheet provides us with a lot of flexibility to continue to execute our growth strategy. Before I turn the call back over to Randy, I wanted to take another look at our EBITDA margin expansion slide from our Investor Day and provide more color on our progression to date and how we expect to achieve the 20% annualized EBITDA run rate as we exit fiscal 2020. So if we turn now to Slide 10, our EBITDA margin from Investor Day. As we discussed in detail on Investor Day, we believe we have a clear path to achieve our annualized 25% margin target as we look forward to 2024. If we start at the bottom of the page, we have either taken actions or have actions in process today that would allow us to end fiscal 2020 with the ability to achieve an annualized run rate of 20%. So let's walk through how this shapes up during the year and our target for future savings. We ended fiscal 2019 with EBITDA margins of 15%. We included 200 basis points of improvement in our guide for 2020. This reflects savings from the elimination of the $9 million of ECS stranded costs and $8 million benefit from restructuring actions we announced and began implementing in 2019. The savings were partially offset by the adjustments to bonus expense. And as we progress through the year, we expect to, number one, complete the restructuring plan announced in 2019 when we identified $12 million to $15 million of annualized savings, we expect to have taken actions by the end of the year to deliver the high-end of the projected savings. This will result in an additional $7 million of annualized savings that we will have completely executed by the back half of this year. We will also have eliminated the additional $4 million in ECS stranded costs by the end of the year and combined these two actions will add an additional 200 basis points of margin based on the midpoint of our 2020 sales guidance. Secondly, we plan to complete the Cortland plant consolidation in the back half of this fiscal year. This will drive $5 million in savings which includes the one-time charge of $2 million in this year to execute the plan or 100 basis points of year-over-year margin improvement. With these actions complete, we will end the year positioned to deliver 20% annualized EBITDA margins in fiscal 2021, again, calculated using the midpoint of our current year sales guidance. So stepping back here, as laid out in our strategic vision at the top of the page, we are targeting another $10 million or approximately 200 basis points from structural cost reductions to right-size the organization as we exit the transition services agreement associated with the ECS transaction. While there will potentially be some opportunities in fiscal 2020, we expect these actions to begin in earnest as we progress through fiscal 2021 and the vast majority completed by the end of 2021. We are also targeting an additional 100 basis points of improvement from the execution of an Enerpac plant optimization project that will likely commence in the back half of fiscal 2021, and we'll have a longer tail to achieving the annualized 100 basis points improvement to ensure that we don't have a negative impact on operations or our ability to deliver products. So collectively, all in through structural cost reductions and manufacturing footprint optimization, we believe we are well positioned to deliver annualized 600 basis points of EBITDA margin improvement as we end fiscal 2023. So that's based on our 2020 guide revenues, these actions will result in an EBITDA margin of approximately 23% with a path to 25% by fiscal 2024 being driven by incremental profit on our targeted 5% compound growth. With that, Randy I'll turn the call back over to you.